Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2015
Date: 2016-09-22
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, free movement of goods, market approval, medicinal product, withdrawal from the market








C_2016347EN.01000401.xml










22.9.2016   


EN


Official Journal of the European Union


C 347/4





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2015
(2016/C 347/04)

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No. 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2015, at their meeting on 29 April 2016:






Annex I


List of new marketing authorisations




Annex II


List of renewed marketing authorisations




Annex III


List of extended marketing authorisations




Annex IV


List of withdrawn marketing authorisations




Annex V


List of suspended marketing authorisations






ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2015:








EU Number


Product


Country


Date of authorisation




EU/1/07/423


Vectibix


Liechtenstein


28.2.2015




EU/1/11/709


Buccolam


Liechtenstein


28.2.2015




EU/1/11/721


Paglitaz


Liechtenstein


28.2.2015




EU/1/11/745


Desloratadine Actavis


Liechtenstein


28.2.2015




EU/1/12/755


Pioglitazone Actavis


Liechtenstein


28.2.2015




EU/1/12/757


Pioglitazone Teva


Liechtenstein


28.2.2015




EU/1/12/758


Pioglitazone Teva Pharma


Liechtenstein


28.2.2015




EU/1/12/760


Bronchitol


Liechtenstein


28.2.2015




EU/1/12/811


Lyxumia


Liechtenstein


28.2.2015




EU/1/13/817


Actelsar HCT


Liechtenstein


28.2.2015




EU/1/13/822


Pheburane


Liechtenstein


28.2.2015




EU/1/13/830


Stribild


Liechtenstein


28.2.2015




EU/1/13/835


Voriconazole Accord


Liechtenstein


28.2.2015




EU/1/13/845


Imatinib Accord


Liechtenstein


28.2.2015




EU/1/13/846


Xtandi


Liechtenstein


28.2.2015




EU/1/13/859


Levodopa-Carbidopa-Entacapone Sandoz


Liechtenstein


28.2.2015




EU/1/13/879


Giotrif


Liechtenstein


28.2.2015




EU/1/13/893


Opsumit


Liechtenstein


28.2.2015




EU/1/14/932


Vantobra


Iceland


17.4.2015




EU/1/14/932


Vantobra


Norway


15.4.2015




EU/1/14/936


Nuwiq


Liechtenstein


28.2.2015




EU/1/14/952


Sevelamer carbonate Zentiva


Iceland


6.2.2015




EU/1/14/952


Sevelamer carbonate Zentiva


Liechtenstein


28.2.2015




EU/1/14/952


Sevelamer carbonate Zentiva


Norway


6.2.2015




EU/1/14/953


Tasermity


Iceland


12.3.2015




EU/1/14/953


Tasermity


Liechtenstein


28.2.2015




EU/1/14/953


Tasermity


Norway


12.3.2015




EU/1/14/957


Cyramza


Iceland


15.1.2015




EU/1/14/957


Cyramza


Liechtenstein


28.2.2015




EU/1/14/957


Cyramza


Norway


13.1.2015




EU/1/14/959


Lynparza


Iceland


14.1.2015




EU/1/14/959


Lynparza


Norway


12.1.2015




EU/1/14/960


Duavive


Iceland


14.1.2015




EU/1/14/960


Duavive


Norway


12.1.2015




EU/1/14/969


Scenesse


Iceland


15.1.2015




EU/1/14/969


Scenesse


Norway


15.1.2015




EU/1/14/970


Rixubis


Iceland


14.1.2015




EU/1/14/970


Rixubis


Norway


13.1.2015




EU/1/14/972


Duloxetine Lilly


Iceland


6.1.2015




EU/1/14/973


Quinsair


Iceland


19.4.2015




EU/1/14/973


Quinsair


Liechtenstein


30.4.2015




EU/1/14/973


Quinsair


Norway


15.4.2015




EU/1/14/974


Cerdelga


Iceland


5.2.2015




EU/1/14/974


Cerdelga


Liechtenstein


28.2.2015




EU/1/14/974


Cerdelga


Norway


10.2.2015




EU/1/14/975


Clopidogrel ratiopharm


Liechtenstein


28.2.2015




EU/1/14/975


Clopidogrel ratiopharm


Norway


5.3.2015




EU/1/14/975


Clopidogrel ratiopharm


Iceland


11.3.2015




EU/1/14/976


Zontivity


Iceland


5.2.2015




EU/1/14/976


Zontivity


Liechtenstein


28.2.2015




EU/1/14/976


Zontivity


Norway


16.2.2015




EU/1/14/977


Rasagilin ratiopharm


Liechtenstein


28.2.2015




EU/1/14/977


Rasagiline ratiopharm


Iceland


22.1.2015




EU/1/14/977


Rasagiline ratiopharm


Norway


9.2.2015




EU/1/14/978


Senshio


Iceland


30.1.2015




EU/1/14/978


Senshio


Liechtenstein


28.2.2015




EU/1/14/978


Senshio


Norway


16.2.2015




EU/1/14/979


Ofev


Iceland


30.1.2015




EU/1/14/979


Ofev


Liechtenstein


28.2.2015




EU/1/14/979


Ofev


Norway


29.1.2015




EU/1/14/980


Cosentyx


Iceland


4.2.2015




EU/1/14/980


Cosentyx


Liechtenstein


28.2.2015




EU/1/14/980


Cosentyx


Norway


30.1.2015




EU/1/14/981


Otezla


Iceland


5.2.2015




EU/1/14/981


Otezla


Liechtenstein


28.2.2015




EU/1/14/981


Otezla


Norway


30.1.2015




EU/1/14/982


Viekirax


Iceland


29.1.2015




EU/1/14/982


Viekirax


Liechtenstein


28.2.2015




EU/1/14/982


Viekirax


Norway


20.1.2015




EU/1/14/983


Exviera


Iceland


29.1.2015




EU/1/14/983


Exviera


Liechtenstein


28.2.2015




EU/1/14/983


Exviera


Norway


20.1.2015




EU/1/14/984


Xadago


Iceland


11.3.2015




EU/1/14/984


Xadago


Liechtenstein


28.2.2015




EU/1/14/984


Xadago


Norway


16.3.2015




EU/1/14/985


Raplixa


Iceland


17.4.2015




EU/1/14/985


Raplixa


Liechtenstein


30.4.2015




EU/1/14/985


Raplixa


Norway


10.4.2015




EU/1/14/986


Xydalba


Iceland


11.3.2015




EU/1/14/986


Xydalba


Liechtenstein


28.2.2015




EU/1/14/986


Xydalba


Norway


2.3.2015




EU/1/14/987


Holoclar


Iceland


11.3.2015




EU/1/14/987


Holoclar


Liechtenstein


28.2.2015




EU/1/14/987


Holoclar


Norway


26.2.2015




EU/1/14/988


Mysimba


Iceland


19.4.2015




EU/1/14/988


Mysimba


Liechtenstein


30.4.2015




EU/1/14/988


Mysimba


Norway


15.4.2015




EU/1/15/1000


Jinarc


Iceland


4.6.2015




EU/1/15/1000


Jinarc


Liechtenstein


30.6.2015




EU/1/15/1000


Jinarc


Norway


12.6.2015




EU/1/15/1001


Akynzeo


Iceland


4.6.2015




EU/1/15/1001


Akynzeo


Liechtenstein


30.6.2015




EU/1/15/1001


Akynzeo


Norway


5.6.2015




EU/1/15/1002


Lenvima


Iceland


15.6.2015




EU/1/15/1002


Lenvima


Liechtenstein


30.6.2015




EU/1/15/1002


Lenvima


Norway


15.6.2015




EU/1/15/1003


Synjardy


Iceland


9.6.2015




EU/1/15/1003


Synjardy


Liechtenstein


30.6.2015




EU/1/15/1003


Synjardy


Norway


17.6.2015




EU/1/15/1004


Voriconazol Hospira


Liechtenstein


30.6.2015




EU/1/15/1004


Voriconazole Hospira


Iceland


4.6.2015




EU/1/15/1004


Voriconazole Hospira


Norway


18.6.2015




EU/1/15/1007


Gardasil 9


Liechtenstein


30.6.2015




EU/1/15/1007


Gardasil 9


Norway


18.6.2015




EU/1/15/1009


Aripiprazole Zentiva


Liechtenstein


30.6.2015




EU/1/15/1010


Duloxetine Mylan


Liechtenstein


30.6.2015




EU/1/15/1011


Pregabalin Sandoz


Liechtenstein


30.6.2015




EU/1/15/1012


Pregabalin Sandoz GmbH


Liechtenstein


30.6.2015




EU/1/15/1013


Lumark


Liechtenstein


30.6.2015




EU/1/15/1014


Opdivo


Liechtenstein


30.6.2015




EU/1/15/989


Orbactiv


Iceland


17.4.2015




EU/1/15/989


Orbactiv


Liechtenstein


30.4.2015




EU/1/15/989


Orbactiv


Norway


15.4.2015




EU/1/15/990


Ikervis


Iceland


17.4.2015




EU/1/15/990


Ikervis


Liechtenstein


30.4.2015




EU/1/15/990


Ikervis


Norway


9.4.2015




EU/1/15/991


Sivextro


Iceland


19.4.2015




EU/1/15/991


Sivextro


Liechtenstein


30.4.2015




EU/1/15/991


Sivextro


Norway


15.4.2015




EU/1/15/992


Saxenda


Iceland


19.4.2015




EU/1/15/992


Saxenda


Liechtenstein


30.4.2015




EU/1/15/992


Saxenda


Norway


9.4.2015




EU/1/15/993


Lixiana


Liechtenstein


30.6.2015




EU/1/15/994


Kengrexal


Iceland


19.4.2015




EU/1/15/994


Kengrexal


Liechtenstein


30.4.2015




EU/1/15/994


Kengrexal


Norway


10.4.2015




EU/1/15/995


Dutrebis


Iceland


19.4.2015




EU/1/15/995


Dutrebis


Liechtenstein


30.4.2015




EU/1/15/995


Dutrebis


Norway


10.4.2015




EU/1/15/996


Ristempa


Iceland


11.5.2015




EU/1/15/996


Ristempa


Liechtenstein


30.4.2015




EU/1/15/996


Ristempa


Norway


13.4.2015




EU/1/15/999


Zykadia


Iceland


4.6.2015




EU/1/15/999


Zykadia


Liechtenstein


30.6.2015




EU/1/15/999


Zykadia


Norway


27.5.2015




EU/2/11/122


Bluevac BTV8


Liechtenstein


28.2.2015




EU/2/11/131


Zulvac 1 Ovis


Liechtenstein


28.2.2015




EU/2/12/140


Poulvac E. coli


Liechtenstein


28.2.2015




EU/2/12/142


Cardalis


Liechtenstein


28.2.2015




EU/2/13/151


Equilis West Nile


Liechtenstein


28.2.2015




EU/2/13/152


ProZinc


Liechtenstein


28.2.2015




EU/2/14/162


Parvoduk


Liechtenstein


28.2.2015




EU/2/14/176


Bovela


Iceland


15.1.2015




EU/2/14/176


Bovela


Norway


23.1.2015




EU/2/14/177


Nexgard Spectra


Iceland


30.1.2015




EU/2/14/177


Nexgard Spectra


Liechtenstein


28.2.2015




EU/2/14/177


Nexgard Spectra


Norway


13.2.2015




EU/2/14/178


Zulvac SBV


Iceland


24.2.2015




EU/2/14/178


Zulvac SBV


Liechtenstein


28.2.2015




EU/2/14/178


Zulvac SBV


Norway


11.3.2015




EU/2/14/179


Suvaxyn CSF Marker


Iceland


9.4.2015




EU/2/14/179


Suvaxyn CSF Marker


Liechtenstein


30.4.2015




EU/2/14/179


Suvaxyn CSF Marker


Norway


9.4.2015




EU/2/14/180


Coliprotec F4


Iceland


15.4.2015




EU/2/14/180


Coliprotec F4


Liechtenstein


30.4.2015




EU/2/14/180


Coliprotec F4


Norway


9.4.2015




EU/2/15/181


Sileo


Liechtenstein


30.6.2015




EU/2/15/181


Sileo


Norway


30.6.2015







ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2015:








EU Number


Product


Country


Date of authorisation




EU/1/00/133


Optisulin


Iceland


18.3.2015




EU/1/00/133


Optisulin


Liechtenstein


28.2.2015




EU/1/00/133


Optisulin


Norway


27.2.2015




EU/1/00/134


Lantus


Iceland


17.3.2015




EU/1/00/134


Lantus


Liechtenstein


28.2.2015




EU/1/00/134


Lantus


Norway


5.3.2015




EU/1/05/308


Aclasta


Iceland


5.2.2015




EU/1/05/308


Aclasta


Liechtenstein


28.2.2015




EU/1/05/308


Aclasta


Norway


17.2.2015




EU/1/05/310


Fosavance


Liechtenstein


30.6.2015




EU/1/05/310


Fosavance


Norway


19.5.2015




EU/1/05/315


Aptivus


Liechtenstein


30.6.2015




EU/1/05/319


Xolair


Liechtenstein


30.6.2015




EU/1/07/423


Vectibix


Iceland


15.1.2015




EU/1/07/423


Vectibix


Norway


29.1.2015




EU/1/08/506


Celvapan


Iceland


3.6.2015




EU/1/08/506


Celvapan


Liechtenstein


30.6.2015




EU/1/08/506


Celvapan


Norway


27.5.2015




EU/1/09/601


Firdapse


Iceland


18.2.2015




EU/1/09/610


Telmisartan Teva


Iceland


14.1.2015




EU/1/09/610


Telmisartan Teva


Liechtenstein


28.2.2015




EU/1/09/610


Telmisartan Teva


Norway


13.1.2015




EU/1/10/612


Revolade


Iceland


30.1.2015




EU/1/10/612


Revolade


Liechtenstein


28.2.2015




EU/1/10/612


Revolade


Norway


29.1.2015




EU/1/10/615


Temozolomide Hospira


Iceland


22.1.2015




EU/1/10/615


Temozolomide Hospira


Liechtenstein


28.2.2015




EU/1/10/615


Temozolomide Hospira


Norway


28.1.2015




EU/1/10/618


Prolia


Iceland


4.2.2015




EU/1/10/618


Prolia


Liechtenstein


28.2.2015




EU/1/10/618


Prolia


Norway


9.2.2015




EU/1/10/620


Ristfor


Iceland


14.1.2015




EU/1/10/620


Ristfor


Norway


13.1.2015




EU/1/10/621


Ristaben


Iceland


14.1.2015




EU/1/10/621


Ristaben


Norway


13.1.2015




EU/1/10/625


Arzerra


Iceland


2.3.2015




EU/1/10/625


Arzerra


Liechtenstein


28.2.2015




EU/1/10/625


Arzerra


Norway


26.2.2015




EU/1/10/627


Raloxifene Teva


Iceland


20.2.2015




EU/1/10/627


Raloxifene Teva


Liechtenstein


28.2.2015




EU/1/10/627


Raloxifene Teva


Norway


27.2.2015




EU/1/10/631


Nivestim


Iceland


15.6.2015




EU/1/10/631


Nivestim


Liechtenstein


30.6.2015




EU/1/10/631


Nivestim


Norway


18.6.2015




EU/1/10/632


Tolura


Iceland


17.4.2015




EU/1/10/632


Tolura


Liechtenstein


30.4.2015




EU/1/10/632


Tolura


Norway


9.4.2015




EU/1/10/633


Topotecan Hospira


Iceland


15.6.2015




EU/1/10/633


Topotecan Hospira


Liechtenstein


30.6.2015




EU/1/10/633


Topotecan Hospira


Norway


15.6.2015




EU/1/10/634


Ribavirin Mylan


Liechtenstein


28.2.2015




EU/1/10/634


Ribavirin Mylan


Norway


27.2.2015




EU/1/10/634


Ribavirin Mylan


Iceland


20.2.2015




EU/1/10/635


Olanzapin Apotex


Liechtenstein


28.2.2015




EU/1/10/635


Olanzapin Apotex


Norway


27.2.2015




EU/1/10/635


Olanzapine Apotex


Iceland


20.2.2015




EU/1/10/636


Daxas


Iceland


12.5.2015




EU/1/10/636


Daxas


Norway


15.5.2015




EU/1/10/637


Leflunomid medac


Liechtenstein


30.4.2015




EU/1/10/637


Leflunomide medac


Iceland


19.4.2015




EU/1/10/637


Leflunomide medac


Norway


9.4.2015




EU/1/10/638


Ozurdex


Iceland


19.4.2015




EU/1/10/638


Ozurdex


Liechtenstein


30.4.2015




EU/1/10/638


Ozurdex


Norway


9.4.2015




EU/1/10/639


Telmisartan Actavis


Liechtenstein


30.6.2015




EU/1/10/640


Sycrest


Iceland


1.6.2015




EU/1/10/640


Sycrest


Liechtenstein


30.6.2015




EU/1/10/640


Sycrest


Norway


3.6.2015




EU/1/10/642


Ibandronsäure Teva


Liechtenstein


30.6.2015




EU/1/10/643


Rapiscan


Iceland


12.5.2015




EU/1/10/643


Rapiscan


Liechtenstein


30.6.2015




EU/1/10/643


Rapiscan


Norway


15.6.2015




EU/1/10/646


VPRIV


Liechtenstein


30.6.2015




EU/1/10/647


Myclausen


Iceland


9.6.2015




EU/1/10/647


Myclausen


Liechtenstein


30.6.2015




EU/1/10/647


Myclausen


Norway


15.6.2015




EU/1/10/651


Clopidogrel HCS


Liechtenstein


30.6.2015




EU/1/10/654


Leflunomid ratiopharm


Liechtenstein


30.6.2015




EU/1/11/666


Libertek


Iceland


12.5.2015




EU/1/11/666


Libertek


Liechtenstein


30.6.2015




EU/1/11/666


Libertek


Norway


15.5.2015




EU/1/11/668


Daliresp


Iceland


12.5.2015




EU/1/11/668


Daliresp


Liechtenstein


30.6.2015




EU/1/11/668


Daliresp


Norway


15.5.2015




EU/1/11/749


Caprelsa


Iceland


30.1.2015




EU/1/11/749


Caprelsa


Liechtenstein


28.2.2015




EU/1/11/749


Caprelsa


Norway


29.1.2015




EU/1/12/764


Pixuvri


Iceland


19.4.2015




EU/1/12/764


Pixuvri


Norway


9.4.2015




EU/1/13/818


Bosulif


Iceland


11.3.2015




EU/1/13/818


Bosulif


Liechtenstein


28.2.2015




EU/1/13/818


Bosulif


Norway


6.3.2015




EU/1/13/848


Erivedge


Iceland


5.6.2015




EU/1/13/848


Erivedge


Liechtenstein


30.6.2015




EU/1/13/848


Erivedge


Norway


15.6.2015




EU/1/13/875


Deltyba


Iceland


12.5.2015




EU/1/13/875


Deltyba


Liechtenstein


30.6.2015




EU/1/13/875


Deltyba


Norway


15.5.2015




EU/1/13/890


Cometriq


Iceland


5.2.2015




EU/1/13/890


Cometriq


Liechtenstein


28.2.2015




EU/1/13/890


Cometriq


Norway


13.2.2015




EU/1/13/901


Sirturo


Iceland


5.2.2015




EU/1/13/901


Sirturo


Liechtenstein


28.2.2015




EU/1/13/901


Sirturo


Norway


10.2.2015




EU/2/05/055


Equilis Te


Liechtenstein


30.6.2015




EU/2/05/055


Equilis Te


Norway


30.6.2015




EU/2/09/103


Respiporc Flu3


Norway


16.1.2015




EU/2/09/104


Zulvac 8 Ovis


Norway


14.1.2015




EU/2/10/106


Bovilis BTV8


Iceland


16.6.2015




EU/2/10/106


Bovilis BTV8


Liechtenstein


30.6.2015




EU/2/10/106


Bovilis BTV8


Norway


26.6.2015




EU/2/10/109


Rhiniseng


Liechtenstein


30.6.2015







ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2015:








EU Number


Product


Country


Date of authorisation




EU/1/00/133/033-035


Toujeo


Iceland


12.5.2015




EU/1/00/133/033-035


Toujeo


Norway


19.5.2015




EU/1/01/195/028-029


Liprolog KwikPen


Iceland


19.2.2015




EU/1/04/303/004


Orfadin


Iceland


3.6.2015




EU/1/04/303/004


Orfadin


Norway


28.5.2015




EU/1/07/319/009


Revlimid


Norway


2.3.2015




EU/1/07/391/009


Revlimid


Iceland


10.3.2015




EU/1/08/469/046-049


Oprymea


Iceland


2.3.2015




EU/1/08/469/050-053


Oprymea


Iceland


2.3.2015




EU/1/08/469/046-049


Oprymea


Norway


25.2.2015




EU/1/08/469/050-053


Oprymea


Norway


25.2.2015




EU/1/12/771/007-009


Zoledronic Acid Teva


Iceland


15.1.2015




EU/1/12/798/005-006


Ibandronic acid Accord


Iceland


19.4.2015




EU/1/12/798/005-006


Ibandronic acid Accord


Norway


10.4.2015




EU/1/13/819/002


Jetrea


Iceland


13.5.2015




EU/1/13/819/002


Jetrea


Norway


13.5.2015




EU/1/96/007/039-042


Humalog KwikPen


Iceland


19.2.2015




EU/2/06/062/005


Cerenia


Norway


29.6.2015




EU/2/07/078/021


Rheumocam


Iceland


4.6.2015




EU/2/07/078/021


Rheumocam


Norway


2.6.2015




EU/2/97/004/050-053


Metacam


Norway


6.5.2015




EU/2/97/004/050-053


Metacam


Iceland


6.5.2015




EU/2/99/014/013-016


Stronghold


Norway


10.4.2015







ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2015:








EU Number


Product


Country


Date of authorisation




EU/1/07/426


Olanzapine Cipla


Norway


21.1.2015




EU/1/08/458


Trevaclyn


Liechtenstein


28.2.2015




EU/1/08/459


Tredaptive


Liechtenstein


28.2.2015




EU/1/08/460


Pelzont


Liechtenstein


28.2.2015




EU/1/09/554


Clopidogrel ratiopharm


Liechtenstein


28.2.2015




EU/1/09/560


Clopidogrel Dura


Liechtenstein


30.6.2015




EU/1/09/560


Clopidogrel Dura


Norway


30.6.2015




EU/1/10/649


Clopidogrel Teva Pharma B.V.


Norway


21.1.2015




EU/1/10/650


Clopidogrel Teva Generics B.V.


Iceland


5.2.2015




EU/1/10/664


Pumarix


Iceland


20.2.2015




EU/1/10/664


Pumarix


Liechtenstein


28.2.2015




EU/1/10/664


Pumarix


Norway


31.1.2015




EU/1/11/686


Rasilamlo


Liechtenstein


30.6.2015




EU/1/11/723


Pioglitazone Krka


Norway


21.1.2015




EU/1/11/748


Docetaxel Mylan (Sunset clause)


Norway


3.2.2015




EU/1/12/754


Sepioglin


Liechtenstein


28.2.2015




EU/1/12/774


Rienso


Iceland


12.5.2015




EU/1/12/774


Rienso


Liechtenstein


30.4.2015




EU/1/12/774


Rienso


Norway


19.5.2015




EU/1/12/804


BindRen


Iceland


13.3.2015




EU/1/12/804


BindRen


Liechtenstein


30.4.2015




EU/1/12/804


BindRen


Norway


14.4.2015




EU/1/13/867


Provenge


Liechtenstein


30.6.2015




EU/1/13/867


Provenge


Norway


15.6.2015




EU/1/97/037


Vistide


Norway


4.2.2015




EU/2/04/049


Purevax RCCh


Iceland


10.2.2015




EU/2/07/071


Slentrol


Iceland


5.2.2015




EU/2/07/071


Slentrol


Liechtenstein


28.2.2015




EU/2/07/071


Slentrol


Norway


30.3.2015




EU/2/11/136


TruScient


Iceland


5.2.2015




EU/2/11/136


TruScient


Liechtenstein


28.2.2015




EU/2/11/136


TruScient


Norway


22.4.2015







ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2015:








EU Number


Product


Country


Date of authorisation




EU/1/13/847/001


MACI


Norway


22.1.2015